Angiosarcoma: lines of therapy

Cancer page →

4 standard-of-care settings across 4 lines and 1 biomarker subgroup. Rows come from the cancer page's standard of care; the grid places each on its line and subgroup.

Line	All comers
Early / localised	1
Advanced, first line	1
Third line and beyond	1
Other settings	1

Early / localised

Subgroup	Setting	Approach	Products and trials	Guideline	Evidence
All comers	Localised cutaneous (scalp, face)	Wide excision where feasible plus wide-field radiotherapy; neoadjuvant or definitive weekly paclitaxel with radiotherapy when surgery is not possible.	IMRT / IGRT (modern external beam)Paclitaxel / nab-paclitaxel		93

Advanced, first line

Subgroup	Setting	Approach	Products and trials	Guideline	Evidence
All comers	Advanced, first line	Weekly paclitaxel (ANGIOTAX) or doxorubicin-based chemotherapy; liposomal doxorubicin in frail patients.	Paclitaxel / nab-paclitaxelANGIOTAXDoxorubicinPegylated liposomal doxorubicin		82

Third line and beyond

Subgroup	Setting	Approach	Products and trials	Guideline	Evidence
All comers	Later lines	Gemcitabine, pazopanib; checkpoint inhibitors (nivolumab plus ipilimumab) for cutaneous scalp and face disease, off label or in trials.	GemcitabinePazopanibNivolumabIpilimumabImmune checkpoint inhibitors		99

Other settings

Subgroup	Setting	Approach	Products and trials	Guideline	Evidence
All comers	Radiation-associated breast angiosarcoma	Total mastectomy with wide skin excision; consider neoadjuvant paclitaxel; re-irradiation is limited by prior dose.	Paclitaxel / nab-paclitaxelDoxorubicin		82

Lines and subgroups are parsed from the setting text of each standard-of-care row and can misclassify an unusual phrasing; the row’s own setting is always shown. Guideline chips reflect the NCCN category and ESMO-MCBS grade recorded on the cancer page, checked on its stated date. Not medical advice.